hOKT3-gamma-1 (ala-ala) [teplizumab], Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Teplizumab (Primary) ; Sirolimus; Tacrolimus
- Indications Islet cell transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.